Mediolanum International Funds Ltd Decreases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

by · The Markets Daily

Mediolanum International Funds Ltd lowered its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 4.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 265,572 shares of the biopharmaceutical company’s stock after selling 11,007 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Royalty Pharma were worth $7,479,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc grew its position in Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,043 shares during the period. Gladius Capital Management LP bought a new stake in Royalty Pharma during the second quarter valued at about $32,000. Blue Trust Inc. increased its position in Royalty Pharma by 362.7% in the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 943 shares in the last quarter. Fidelis Capital Partners LLC bought a new position in shares of Royalty Pharma in the first quarter worth about $46,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 655 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX opened at $26.95 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The stock has a market capitalization of $16.10 billion, a price-to-earnings ratio of 20.11, a PEG ratio of 4.03 and a beta of 0.46. The company has a fifty day moving average of $28.02 and a 200 day moving average of $27.63. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The firm had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter last year, the business posted $0.85 earnings per share. As a group, sell-side analysts forecast that Royalty Pharma plc will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 annualized dividend and a yield of 3.12%. Royalty Pharma’s payout ratio is presently 62.69%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RPRX shares. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. The Goldman Sachs Group increased their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Citigroup lowered their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Morgan Stanley increased their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $41.67.

Check Out Our Latest Stock Report on Royalty Pharma

Royalty Pharma Profile

(Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Read More

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX – Free Report).